Safe Orthopaedics announces its revenues for the third quarter of 2020 : €943k
08 Octobre 2020 - 05:35PM
Safe Orthopaedics announces its revenues for the third quarter of
2020 : €943k
- Sharp increase for quarterly direct sales : +28%
- Worldwide sales still hit by the pandemic
- First effects of LCI Medical acquisition
Éragny-sur-Oise, France, October 8,
2020, 17h35 CEST – Safe Orthopaedics (FR0013467123 –
ALSAF), a company specializing in the design and marketing of
single-use implants and instruments for the minimally invasive
treatment of spinal fracture conditions, is today announcing its
revenues for the third quarter of 2020 and its cash position at
September 30, 2020.
In thousands of euros |
Q3 2020(3 months) |
|
Q3 2019(3 months) |
9M 2020 |
|
9M 2019 |
Direct sales |
618 |
+28% |
484 |
1
500 |
+1% |
1
492 |
Indirect sales |
325 |
-52% |
675 |
1
173 |
-31% |
1
708 |
Total revenues |
943 |
-19% |
1 159 |
2 673 |
-16% |
3 201 |
Safe Orthopaedics’ third quarter in 2020 were
€943k, a decrease of 19% compared to the third quarter 2019,
entirely due to the impact of successive sanitary measures for the
global pandemic in different countries. Indirect sales from
distributors produced €325k, a decrease of 44% compared to the
third quarter 2019. The sales made under the Japanese agreement,
strategical partnership initiated in 2019, amounted to €46k versus
€296k for the third quarter 2019.Direct sales (France, Germany and
United Kingdom) amounted to €618k versus €484k, an increase of +28%
following the integration of LCI Medical on July 24th, 2020; €450k
at constant structure.
The cumulated net sales on September 30th, 2020,
amounts to €2 573k, a decrease of 16% compared to 2019. Direct
sales increased slightly (+1%) while indirect sales decrease by 31%
due to the global pandemic. Cumulated sales under the Japanese
contract amounted to €387k versus €757k for the same period in
2019.
“In spite of the pandemic, the turnover for
direct sales during the third quarter show a growth of 28%,
recovering the economic growth thanks, in particular, to the
acquisition of LCI Medical end of July. The sanitary crisis on the
international market still strongly impacts the prospection work
with surgeons of our distributors, severely affecting our indirect
sales for this third semester” comments Pierre Dumouchel,
President of Safe Orthopaedics. “The transformation of the
industrial site in Fleurieux-sur-l’Arbresle is well underway and
will allow, on the fourth quarter of 2020, to accelerate the
commercial launch of new technologies and to benefit from shorter
production cycles. The recovering of the economic growth for direct
sales and emerging new industrial partnership allow us to consider
a return to economic growth in a still unstable context of
Covid-19”. Cash
Position
At the end of the third quarter 2020, Safe
Orthopaedics had cash of €575k versus €581k a year earlier. As a
reminder, the General Assembly of Shareholders approved on June
7th, 2019, a €12.15M financing line of which 5 monthly installments
of €450k each remain to be paid.
Next financial publication
Annual turnover 2020, Monday, January 14th, 2021
(post market).
About Safe
Orthopaedics
Founded in 2010, Safe Orthopaedics is a French
medical technology company, a pioneer of the design and marketing
of innovative ready-to-use technologies (single-use implants and
instruments) for spinal fractures treatments. The company develops
and manufactures kits combining sterile implants and single-use
instruments, available at any time for the surgeon. These
technologies enable minimally invasive approach, reducing the risk
of cross contamination and infection, in the interest of the
patient with a positive impact on hospitalization durations and
costs. Protected by 17 patent families, the SteriSpineTM PS are CE
marked and FDA approved. Safe Orthopaedics has its headquarters
close to Paris (95610 Eragny-sur-Oise – France) has subsidiaries in
the UK, Germany, United States and in the Lyon area where the
manufacturing company is located. The Group employs around 150
employees.
For more information:
www.SafeOrthopaedics.com
Contacts
Safe
Orthopaedics
François-Henri Reynaud
Chief Financial and Administrative Officer
Tél. : +33 (0)1 34 21 50
00
investors@safeorthopaedics.com
Press RelationsUlysse
CommunicationBruno Arabian / +33 (0)6 87 88 47 26 /
barabian@ulysse-communication.comNicolas Daniels / +33 (0)6 63
66 59 22 / ndaniels@ulysse-communication.com
SAFE (EU:ALSAF)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
SAFE (EU:ALSAF)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024